GlassScriptPhysician profile
Grant C Lewis
NPI 1215009287
$13,125.33
in general payments reported to CMS, 2019-2025
70 companies · $2,278 in 2025
The $2,278 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,795 · 2020: $552 · 2021: $619 · 2022: $1,908 · 2023: $1,973 · 2024: $3,001 · 2025: $2,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,165 · Education: $86.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,165.19 |
| Education | $86.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,348.57 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $1,341.52 | 2019-2025 | |
| Pfizer INC. | $796.23 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $662.93 | 2019-2025 | Calquence, Imfinzi, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $659.76 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Amgen INC. | $609.18 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Janssen Biotech, INC. | $532.19 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Genentech USA, INC. | $524.34 | 2019-2025 | Avastin, Rozlytrek, Alecensa |
| Gilead Sciences, INC. | $428.41 | 2021-2025 | Trodelvy |
| Eisai INC. | $382.32 | 2019-2025 | |
| Daiichi Sankyo INC. | $356.08 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Abbvie INC. | $323.98 | 2019-2025 | |
| Seagen INC. | $293.75 | 2019-2023 | Tukysa, Adcetris, Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $293.04 | 2019-2025 | |
| Astellas Pharma US INC | $290.92 | 2019-2024 | Xtandi |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grant Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.